BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11422025)

  • 1. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
    Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathôt RA; Mulder JW; Meenhorst PL; Beijnen JH
    Br J Clin Pharmacol; 2001 Jun; 51(6):631-5. PubMed ID: 11422025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
    Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
    Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
    Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
    Pai MP; Schriever CA; Diaz-Linares M; Novak RM; Rodvold KA
    Pharmacotherapy; 2004 May; 24(5):592-9. PubMed ID: 15162893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
    Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
    Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
    van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
    AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
    Kaeser B; Zandt H; Bour F; Zwanziger E; Schmitt C; Zhang X
    Antimicrob Agents Chemother; 2009 Feb; 53(2):609-14. PubMed ID: 19015329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].
    Tsuchiya K; Hirabayashi Y; Imai K; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Yasuoka A; Oka S; Kimura S
    Kansenshogaku Zasshi; 2003 Jun; 77(6):436-42. PubMed ID: 12872693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
    Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Gazzard B; Pozniak A
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1376-84. PubMed ID: 15483467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients.
    Boffito M; Jackson A; Pozniak A; Giraudon M; Kulkarni R; Abelardo MC; Patel IH; Morcos PN
    Drugs R D; 2015 Mar; 15(1):141-53. PubMed ID: 25742730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
    Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.